A pharmacoeconomic model for the treatment of influenza

PharmacoEconomics

Volumn 16, Issue SUPPL. 1, 1999, Pages 73-84

  Mauskopf, Josephine A ^a   Cates, Sheryl C ^a   Griffin, Adrian D ^b  

^a RTI INTERNATIONAL   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT; DECONGESTIVE AGENT; NON PRESCRIPTION DRUG; RIMANTADINE; ZANAMIVIR;

AGED; COMPUTER MODEL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HIGH RISK POPULATION; HUMAN; INFLUENZA; PHARMACOECONOMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ALGORITHMS; ANTIVIRAL AGENTS; COMPUTER SIMULATION; ECONOMICS, PHARMACEUTICAL; HOSPITALIZATION; HUMANS; INFLUENZA, HUMAN; TREATMENT OUTCOME;

EID: 0032735779     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916001-00010     Document Type: Conference Paper

References (21)

1. Levy E, Levy P. Anti-influenza vaccination for active persons (25-64 years): a cost-benefit study. Rev Epidemiol Santé Publique 1992; 40: 285-95
2. Vutuc C, Kunze M. Influenza: incidence and costs of inpatient treatment. Fortschr Med 1993; 111: 508-9
3. Schoenbaum SC. Economic impact of influenza. Am J Med 1987; 295: 759-65
4. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993; 153: 2105-11
5. Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR 1998; 47 Suppl. (RR-6): 1-26
6. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337 (13): 874-80
7. Treanor JJ, Vrooman PS, Hayden FG, et al. Efficacy of oral GS4104 in treating acute influenza. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 1998 Sep 24-27; San Diego, 1998
8. The MIST study group. Randomized trial of efficacy and safety of inhaled zanamivir in the treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81
9. Department of Health and Human Services. National Ambulatory Medical Care Survey. Washington DC: Department of Health and Human Services, 1990
10. Department of Health and Human Services. National Hospital Discharge Survey. Washington DC: Department of Health and Human Services, 1990
11. Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine HCI and rimantadine HCI in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 1969; 28 (11): 579-84
12. Hayden FG, Hall WJ, Douglas RG. Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J Infect Dis 1980; 4 (5): 535-42
13. Silagy CA, Griffin AD, Lacey LA, et al. Impact of zanamivir on health status, productivity and healthcare resource use in patients with influenza. Annual Meeting of the Infectious Disease Society of America; 1998 Nov 12-15: Denver, CO
14. Red Book. 1995 Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc., 1995
15. US Bureau of the Census. Statistical abstract of the United States: 1994, 114th ed. Washington, DC: US Bureau of the Census, 1994
16. Schoenbaum S, McNeil B, Kavet J. The swine-influenza decision. N Engl J Med 1976; 295: 759-65
17. Jefferson T, Demicheli V. Economic evaluation of influenza vaccination and economic modelling: can results be pooled? Pharmacoeconomics 1996; 9 Suppl. 3: 67-72
18. US Congress, Office of Technology Assessment (OTA). Cost effectiveness of influenza vaccination. Washington, DC: US Government Printing Office, 1981. Publication No: OTA-H-152
19. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986; 76 (7): 761-5
20. Fleming DM. The impact of three influenza epidemics on primary care in England and Wales. Pharmacoeconomics 1996; 9 Suppl. 3: 38-45
21. Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992; 7 (1): 26-37